Category 2 prohibited) have not been issued GHRP-2 and GHRP-6 are listed as Discontinued in terms of formal drug development programmes
In our study, most dermatologists prefer oral Glutathione, with IV use much less common due to safety concerns. This preference reflects the medical communitys risk-benefit assessment, where the potential for serious adverse events with injectable forms outweighs uncertain cosmetic benefits
Growing Complexity in Site Operations Sites now manage an average of 22 distinct sponsor/CRO platforms per trial spending roughly 12 hours each week on redundant data entry according to ACRPs March 2025 survey
however, clinical trials in humans are very limited
Remember this is a PEPTIDE (messenger), not a trans-dermal filler
In a randomized, dounble-blind clinical trial, we have shown that the innovative Sucrosomial B12 formulation rapidly achieve considerably higher and maintained circulatory B12 levels, overcoming the deficiency-borderline threshold (200300 pg/mL) within 24 h with a single 1,000 g dose